- High legality with over 30 regulatory legal documents
- Heavy dependence on imported raw materials (65-70% of APIs from abroad)
- Fierce competition between domestic enterprises and 50+ multinational companies
- Developed distribution network with over A40,000 pharmacies nationwide
- Trend shift from treatment to prevention and healthcare
The Vietnamese pharmaceutical stock market is growing strongly, creating attractive investment opportunities for both new and experienced investors. This article provides an in-depth analysis of current trends, potential stock codes, and effective investment strategies specifically for the Vietnamese market in 2025.
Overview of pharmaceutical stocks in Vietnam
The pharmaceutical stock market in Vietnam has experienced significant fluctuations during the 2023-2025 period. With a population of nearly 100 million and per capita healthcare spending increasing by 12.7% annually, Vietnam’s pharmaceutical industry is growing rapidly, expected to achieve a compound annual growth rate (CAGR) of 8-10% from now until 2030.
There are currently 23 pharmaceutical companies listed on Vietnam’s stock exchanges (HOSE, HNX, and UPCOM), with a total market capitalization of approximately 90 trillion VND. These companies operate in various segments, from generic drug production, functional foods to pharmaceutical distribution and research and development.
Investing in pharmaceutical stocks is increasingly attractive due to high defensive characteristics during periods of economic volatility and long-term growth potential. Data from SSI Research shows that during the market correction period of 2023-2024, many pharmaceutical stocks still maintained positive growth, demonstrating the stability of this industry.
| Characteristics | Current state of Vietnam’s pharmaceutical industry (2025) |
|---|---|
| Total market value | Approximately 8.2 billion USD |
| Growth rate | 9.5% (2024-2025) |
| Number of listed companies | 23 companies |
| Domestic/imported drugs ratio | 48%/52% |
| Healthcare spending per capita | 215 USD/year |
Characteristics of Vietnam’s pharmaceutical market
Vietnam’s pharmaceutical market has unique characteristics that investors need to understand before deciding to invest in pharmaceutical stocks. After the COVID-19 pandemic, the industry has undergone many changes in both market structure and consumer behavior.
The first notable point is the strict legal framework. Pharmaceutical companies are subject to strict regulation from the Drug Administration of Vietnam – Ministry of Health, with many regulations on quality, registration, and drug circulation. Circular 29/2023/TT-BYT on drug procurement (replacing Circular 15/2019) has created a new competitive environment among manufacturers.
Analysis of factors affecting pharmaceutical stocks
Pharmaceutical stock prices are influenced by many specific factors. Unlike many other industries, pharmaceutical stocks not only reflect business results but also depend on policy factors, science, and consumer trends.
Macroeconomic factors affecting pharmaceutical company stocks
Healthcare policy plays a key role in shaping Vietnam’s pharmaceutical market. The National Strategy for Pharmaceutical Industry Development until 2030 and vision to 2045 has set a goal of increasing the proportion of domestically produced drugs to 80%, creating momentum for domestic pharmaceutical companies.
In addition, new regulations on drug procurement in Circular 29/2023/TT-BYT (effective from January 1, 2024) have created advantages for companies with factories meeting EU-GMP or PIC/S-GMP standards. According to data from the Drug Administration, currently only 5 Vietnamese pharmaceutical companies meet EU-GMP standards and 9 companies meet PIC/S-GMP, creating a clear competitive advantage.
| Macroeconomic factors | Impact on pharmaceutical stocks |
|---|---|
| Circular 29/2023/TT-BYT | Priority for drug manufacturers meeting EU-GMP, PIC/S-GMP standards |
| VND/USD exchange rate fluctuations (+5.2% in 2024) | Increased imported raw material costs, reduced profit margins by 1.5-2.5% |
| Health insurance (coverage reaching 92.7% of population) | Increased drug consumption through ETC channel (hospitals) |
| Healthcare inflation (6.3% in 2024) | Pressure on drug prices and production costs |
| Digital healthcare transformation regulations | Promoting investment in technology and pharmaceutical e-commerce |
Population aging is occurring rapidly in Vietnam, with the proportion of people over 60 having increased from 12% in 2020 to 13.3% in 2025, and expected to reach 21% by 2035. According to statistics from the Ministry of Health, elderly people consume on average 3.2 times more medications than working-age individuals, especially drugs for chronic diseases such as cardiovascular, diabetes, and bone and joint diseases.
Specific microeconomic factors of pharmaceutical companies
The business performance of each pharmaceutical company depends on many internal factors. Notably, companies with high revenue from the OTC channel (pharmacies) are usually less affected by changes in drug procurement policies, but face higher marketing costs (15-20% of revenue) and more intense competition.
Analysis from VNDirect shows that companies with OTC revenue ratios above 70% such as DHG, TRA have gross profit margins ranging from 45-48%, significantly higher than companies dependent on the ETC channel (35-40%). However, the selling expenses of the OTC group are also 1.5-2 times higher, causing net profit margins to not differ much between the two groups.
- Product portfolio (quantity, diversity, exclusivity) determines competitiveness
- OTC/ETC revenue structure affects profit margins and stability
- Factory standards (WHO-GMP, EU-GMP, PIC/S-GMP) directly impact bidding capability
- R&D capacity determines product innovation ability (currently only 5% of Vietnamese pharmaceutical companies invest over 5% of revenue in R&D)
- Inventory and debt management efficiency affects cash flow and ROA
A less noticed point but one that has a major impact on pharmaceutical company prospects is the expiration cycle of patent protection for original drugs. In 2025-2027, many blockbuster drugs with global revenues of billions of USD will expire, creating opportunities for generic drug manufacturers in Vietnam. According to IQVIA, generic drug prices are typically only 30-40% of original drug prices, but provide good profit margins for domestic manufacturers.
Top potential pharmaceutical stock codes
Vietnam’s pharmaceutical stock market has many attractive codes worthy of investor consideration in 2025. Below is a detailed analysis of some outstanding pharmaceutical stocks based on recent business results, development strategies, and current valuations.
| Stock code | Main business area | Strengths | Points to note |
|---|---|---|---|
| DHG | Generic drugs, functional foods | 5% market share of the entire market, ROE 18.2%, EU-GMP certified factory, R&D support from Taisho | Slowing growth (5.7% in 2024), high P/E (18.5x) |
| TRA | Pharmaceuticals, cosmetics, functional foods | Revenue growth 12.3% (2024), new factory meeting PIC/S-GMP, strong R&D | High debt ratio (0.9x), profit margin affected by depreciation costs |
| DMC | Antibiotics, vitamins, minerals | Exports to 14 markets, stable growth 8-10%/year, ROE 15.6% | Dependence on imported raw materials (75% of COGS), low profit margins |
| DBD | Cardiovascular, digestive drugs | Advantage in Central region, low costs, stable dividends 7-8%/year | Small size (market cap 820 billion VND), low liquidity (45,000 shares/day) |
| OPC | Medicinal herbs, herbal medicines | 35ha raw material area, benefits from trend of using natural medicines | Competition with Chinese products, high seasonality, low P/E (9.5x) |
When analyzing pharmaceutical company stocks, investors need to pay attention to some important financial indicators. According to VCBS research, pharmaceutical companies with ROE above 15%, gross profit margin above 40%, and stable dividend ratio (above 5%) often provide good investment performance in the long term. Significant fluctuations in exchange rates and API raw material prices in 2023-2024 have put pressure on the profit margins of many businesses, but have gradually stabilized in Q2/2025.
M&A (mergers and acquisitions) is a prominent trend in Vietnam’s pharmaceutical industry. In the 2023-2025 period, there have been 8 major transactions with a total value of over 500 million USD. Notable examples include Taisho (Japan) increasing its ownership in DHG to 51.8%, SK Group (South Korea) buying 24.9% of Imexpharm shares, and Stada Group (Germany) acquiring 100% of Phytopharma. These transactions often stimulate stock prices to increase by 20-30% in the short term and create new growth momentum in the medium-long term.
Investment strategies for pharmaceutical company stocks
Investing in pharmaceutical company stocks requires specific strategies based on in-depth analysis of industry characteristics and personal goals. Depending on risk appetite and investment time horizon, investors can choose different strategies to optimize returns.
| Strategy | Characteristics | Suitable for |
|---|---|---|
| Value investing | Choose pharmaceutical stocks with low P/E (below 15x), P/B below 2x, stable dividends (above 5%) | Capital preservation investors, preferring steady income |
| Growth investing | Prioritize companies with revenue growth above 15%/year, large R&D investments, expanding exports | Investors accepting high valuations (P/E 18-25x) in exchange for growth |
| Catalyst-based investing | Focus on events such as new drug approvals, high-standard factory certifications, M&A | Medium-term investors with ability to analyze event impacts on stock prices |
| Industry diversification | Allocate capital across multiple segments: manufacturing, distribution, generic drugs, specialized drugs | Investors wanting to minimize company-specific risks |
Combining fundamental and technical analysis is an effective approach when investing in pharmaceutical stocks. Analyzing the latest quarterly financial reports, especially revenue growth rates, profit margins, and cash generation capability will help identify businesses with solid foundations. The Pocket Option platform provides many technical analysis tools such as RSI, MACD, and Bollinger Bands to identify price trends and optimal market entry times.
Data from VDSC shows that during the 2020-2024 period, the DCA (Dollar-Cost Averaging) strategy applied to a basket of Vietnam’s 10 largest pharmaceutical stocks has yielded an average return of 12.5%/year, outperforming the VN-Index (9.7%/year). This strategy is particularly effective during periods of strong market volatility such as 2022-2023.
- Clearly define investment objectives: dividend income, capital appreciation, or a combination of both
- Diversify portfolio with appropriate ratios: 40-50% industry leaders, 30-40% growth companies, 10-20% potential stocks
- Monitor business results announcement schedules, shareholder meetings, and important events
- Pay attention to pharmaceutical industry regulatory changes that will take effect in the next 6-12 months
A different perspective is investing in pharmaceutical companies with potential to become M&A targets. According to KPMG’s report, multinational pharmaceutical groups typically pay a premium of 25-40% when conducting M&A transactions in emerging markets like Vietnam. Identifying signs include: companies with large market share in specific segments, extensive distribution networks, unique product portfolios, and export potential, but without foreign strategic shareholders or with low foreign ownership ratios.
Risk management when investing in the pharmaceutical sector
Although considered a defensive sector, investing in pharmaceutical stocks still contains many specific risks that investors need to identify and manage effectively. Understanding these risks will help build more sustainable investment strategies.
| Risk type | Detailed description | Specific management measures |
|---|---|---|
| Legal risk | Changes in drug registration regulations, price controls, procurement (Circular 29/2023 has caused major fluctuations in ETC market share) | Monitor draft legal documents from the Ministry of Health, prioritize companies with diverse revenue structure between OTC/ETC |
| Competition risk | Competition from 217 domestic enterprises and 54 multinational companies, drug imports increased 14.5% in 2024 | Choose companies with sustainable competitive advantages: strong brands, product exclusivity, proprietary technology |
| Raw material risk | API prices from China, India fluctuated 15-20% in 2023-2024, supply chain disruption issues | Prioritize companies with diverse suppliers, reasonable inventory (3-4 months of production), long-term contracts |
| Exchange rate risk | VND depreciated 5.2% against USD in 2024, directly affecting import costs | Analyze the company’s exchange rate hedging capability, pricing power, and ability to pass costs to consumers |
| R&D risk | High R&D failure rate in pharmaceutical industry (75-80%), large costs affecting profits | Evaluate the actual research portfolio, avoid companies placing too many expectations on unproven new products |
A specific risk of the pharmaceutical industry is the lengthy drug approval and registration process. According to data from the Drug Administration, the average time to register a new generic drug in Vietnam is 12-18 months, while new drugs require 24-36 months. This delay can significantly affect business plans and expected profits of pharmaceutical companies.
When trading pharmaceutical stocks on Pocket Option, investors should make full use of risk management tools. The automatic Stop Loss feature helps limit losses when the market moves unfavorably, while Take Profit ensures profit-taking when price targets are reached. Pocket Option allows setting these levels with high flexibility, suitable for each specific investment strategy.
An effective risk management strategy is to follow the 5-10-20 asset allocation principle. Accordingly, do not invest more than 5% of the portfolio in a single pharmaceutical stock, no more than 10% in a specific segment (such as generic drugs, specialized drugs, distribution), and no more than 20% of the total portfolio in the entire pharmaceutical sector. This principle has been proven to help minimize concentration risk in many investment portfolio management studies.
Prospects for Vietnam’s pharmaceutical market
Vietnam’s pharmaceutical market is facing many positive prospects in the 2025-2030 period, bringing attractive opportunities for long-term investors in pharmaceutical stocks. Many macro and micro factors are converging, creating sustainable growth momentum for this industry.
Key growth drivers
Population aging is the most important factor driving pharmaceutical demand in Vietnam. Data from the General Statistics Office shows that the proportion of people over 60 will increase from 13.3% in 2025 to about 21% by 2035. This population group consumes 3.2 times more drugs than the working-age population, especially drugs for chronic diseases such as cardiovascular, diabetes, and cancer.
Average per capita income in Vietnam is expected to increase from 4,100 USD (2024) to 5,500-6,000 USD by 2030, accompanied by strong growth in healthcare spending. According to BMI Research, per capita healthcare spending in Vietnam is expected to increase from 215 USD (2025) to about 350 USD by 2030, creating a major driver for the pharmaceutical market.
| Major trends | Impact on pharmaceutical industry | Specific investment opportunities |
|---|---|---|
| Increase in non-communicable diseases | Demand for chronic treatment drugs increasing 12-15%/year, accounting for 65% of treatment costs | Companies specializing in cardiovascular, diabetes, cancer like DHG, IMP, TV2 |
| Digital transformation in healthcare | 25% of prescriptions issued via digital platforms, smart distribution systems reducing costs by 12% | Companies investing heavily in technology, e-commerce like PME, DBD |
| RCEP and FTAs | Vietnam’s pharmaceutical exports increased 18.5% in 2024, expanding to 36 markets | Companies with export capacity and EU-GMP certification like TRA, DMC |
| Development of domestic medicinal herbs | Medicinal herb cultivation area increasing from 35,000ha (2024) to 50,000ha (2030) | Companies specializing in herbal medicines like OPC, TRA |
The Vietnamese government has issued the National Strategy for Pharmaceutical Industry Development until 2030, setting a goal to increase the proportion of domestically produced drugs from the current 48% to 80% by 2030. This program is supported by many preferential policies on taxes, land, and capital for enterprises investing in high-tech pharmaceutical production and API raw materials.
The RCEP Agreement and other FTAs that Vietnam has signed are opening up opportunities for pharmaceutical exports to regional and international markets. In 2024, Vietnam’s pharmaceutical export value reached 235 million USD, increasing 18.5% compared to 2023. The main export markets include ASEAN, Japan, Russia, and some African countries. Businesses with internationalization strategies and meeting international quality standards will benefit greatly from this trend.
- Vietnam’s pharmaceutical market is expected to reach 16.5 billion USD by 2030 (CAGR 9.2%)
- The proportion of domestically produced drugs will increase from 48% to 80% by 2030 according to the national strategy
- FDI inflows into the pharmaceutical industry reached 857 million USD during 2021-2024, expected to double by 2030
- The biopharmaceuticals segment is growing fastest, reaching 25%/year
Besides positive prospects, Vietnam’s pharmaceutical industry still faces challenges with limited research and development capacity and dependence on imported raw materials. Currently, only 5 Vietnamese pharmaceutical companies invest more than 5% of revenue in R&D, much lower than the average of 15-20% of multinational pharmaceutical companies. This is a major barrier to developing specialized products and high-tech drugs.
How to trade pharmaceutical stocks on the Pocket Option platform
Pocket Option provides an advanced trading platform helping Vietnamese investors access pharmaceutical stocks conveniently and efficiently. With a friendly interface and many in-depth analytical tools, Pocket Option meets the needs of both new and professional investors.
To get started, investors need to register an account on the Pocket Option website or mobile application, complete the identity verification process according to KYC regulations. Then, deposit funds into the trading account through many popular payment methods in Vietnam such as domestic bank cards, Momo e-wallet, ZaloPay, or bank transfer.
| Trading step | Detailed instructions | Important notes |
|---|---|---|
| 1. Market research | Use fundamental and technical analysis tools on Pocket Option to evaluate pharmaceutical stocks | Combine information from industry reports by SSI, VCBS, and other reliable sources |
| 2. Strategy building | Define objectives (growth/dividend), holding period, risk acceptance level (2-5% capital/trade) | Clearly write down trading plan with specific entry, exit, and stop-loss levels |
| 3. Open trading position | Select pharmaceutical stock code, order type (Market/Limit), appropriate volume and leverage (if used) | For low liquidity stocks like DBD, OPC, should use Limit Orders |
| 4. Set protection | Set Stop Loss (5-10% below purchase price) and Take Profit (15-25% above purchase price) according to average volatility | Do not move Stop Loss further away from initial level when trade is losing |
| 5. Monitor and adjust | Use Pocket Option mobile app to monitor trades, set alerts when price reaches technical thresholds | Update strategy when new information about policies, business results emerges |
The Pocket Option platform provides many modern technical analysis tools particularly suitable for pharmaceutical stocks. Investors can use momentum indicators like RSI to identify overbought/oversold conditions, MACD to identify trend movements, and Bollinger Bands to determine price volatility ranges and potential breakout points.
A unique advantage of trading pharmaceutical stocks on Pocket Option is 24/5 market access, not limited by HOSE and HNX trading hours (9:00-15:00). This allows investors to respond promptly to international news affecting the pharmaceutical industry (such as drug approvals, global M&A) even after official trading hours in Vietnam.
Pocket Option provides a demo account with 10,000 virtual USD, allowing investors to practice pharmaceutical stock trading strategies in a risk-free environment. This is an effective way to become familiar with the platform and validate strategies before investing real money. Additionally, the platform offers many free online courses on technical and fundamental analysis, with in-depth analyses of Vietnam’s pharmaceutical industry conducted by leading experts.
For long-term investors in pharmaceutical stocks, Pocket Option provides an automatic DCA tool, allowing setup of periodic purchase plans with fixed amounts weekly or monthly. This feature helps implement the cost averaging strategy in a disciplined manner, minimizing the impact of short-term price volatility and market psychology.
Conclusion
Pharmaceutical stocks in Vietnam are increasingly becoming an attractive destination for investors thanks to the combination of defensive characteristics and long-term growth potential. With drivers from population aging, income growth, and supportive government policies, Vietnam’s pharmaceutical industry is forecast to maintain 8-10% growth in the next decade, creating a solid foundation for the development of domestic pharmaceutical companies.
To invest effectively in pharmaceutical stocks, Vietnamese investors need to build comprehensive strategies based on in-depth analysis of industry characteristics, market trends, and macroeconomic factors affecting businesses. Careful evaluation of core financial indicators such as ROE, profit margins, debt ratios along with competitive capacity and development strategy of each company is the key factor in selecting potential stocks.
The Pocket Option trading platform provides comprehensive tools and advanced features helping Vietnamese investors access, analyze, and trade pharmaceutical stocks conveniently and efficiently. From modern technical analysis tools to free demo accounts and in-depth courses, Pocket Option meets the needs of both beginning investors and experienced ones in their journey of investing in this potential-filled field.
In the context of digital transformation and global integration of Vietnam’s pharmaceutical industry, businesses with innovative strategies, investment in R&D, and export market expansion will be the most attractive investment choices. Smart investors need to continuously update knowledge, monitor industry trends, and adjust investment strategies to capture optimal opportunities from pharmaceutical stocks in the journey of seeking sustainable profits.
FAQ
Which pharmaceutical stock codes have the best growth potential in Vietnam in 2025?
Leading pharmaceutical stocks like DHG, TRA, and DMC are showing positive potential thanks to solid financial foundations and clear development strategies. In particular, TRA with revenue growth rate of 12.3% (2024) and a new factory meeting PIC/S-GMP standards is being highly rated by many analysts. DMC with its export strategy to 14 markets is also an attractive choice for long-term investment.
How to accurately assess the value of a Vietnamese pharmaceutical stock?
Evaluating Vietnamese pharmaceutical stocks requires comprehensive analysis of factors: financial indicators (ROE >15%, gross profit margin >40%), revenue structure (OTC/ETC ratio), achieved production standards (WHO-GMP, EU-GMP, PIC/S-GMP), distribution network, product portfolio, and innovation capability. Pay special attention to adaptability to Circular 29/2023/TT-BYT on drug procurement and strategies to respond to API raw material price fluctuations.
Why is investing in pharmaceutical stocks considered an effective defensive strategy during volatile periods?
Pharmaceutical stocks are considered defensive because demand for drugs and healthcare services is relatively stable in all economic conditions. Data from 2022-2023 shows that when the VN-Index decreased by 32.8%, the pharmaceutical industry index only decreased by 12.6%. Pharmaceutical companies typically have stable cash flow with average net profit margins of 12-15%, low debt ratios, and ability to pay regular dividends (5-8%/year), helping protect portfolio value during recessions.
What specific tools does Pocket Option provide to analyze and trade Vietnamese pharmaceutical stocks?
Pocket Option provides a comprehensive toolkit for Vietnamese pharmaceutical stock investors, including: multi-timeframe technical charts with 38 technical indicators (particularly effective are RSI, MACD, and Bollinger Bands), automated market scanner detecting price patterns, intelligent alert system, and fundamental analysis reports on 23 listed pharmaceutical companies. Additionally, the platform also provides automatic DCA tools and copy trading features from successful investors in the pharmaceutical field.
Which strategy is most suitable for beginners investing in Vietnamese pharmaceutical stocks?
New investors should apply value investing strategy combined with DCA (Dollar-Cost Averaging) method. Start with 3-5 large, reputable pharmaceutical stocks like DHG, IMP, TRA with stable business history and regular dividends above 5%/year. Allocate capital evenly each month to minimize price volatility risk. Before investing real money, practice for at least 3 months with a 10,000 USD demo account on Pocket Option, focus on understanding the specifics of Vietnam's pharmaceutical industry and invest maximum 20% of portfolio in this sector.